Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

We have a library of over 200 quality standards and a single menu of indicators. They can be used to help define and measure quality in health, public health and social care. They can be used by ...

Suggested remit: To appraise the clinical and cost effectiveness of Iclepertin within its marketing authorisation for treating for schizophrenia.

A list of downloadable documents created during development.

Suggested remit: To appraise the clinical and cost effectiveness of Doxecitine–doxribtimine within its marketing authorisation for treating Thymidine Kinase 2 (TK2) deficiency.

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

Suggested remit: To appraise the clinical and cost effectiveness of Glycopyrronium bromide cream within its marketing authorisation for treating hyperhidrosis.

NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...

Our final draft guidance recommends elacestrant (also called KORSERDU and made by Menarini Stemline) for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) ...

NICE's assessment of digital technologies to support self-management of chronic obstructive pulmonary disease (COPD) recommends that Active+me REMOTE, Clinitouch, COPDhub, COPDPredict, Lenus COPD ...